How Much Does Sermorelin Cost? (2026)

Sermorelin sits in an unusual position among compounded peptides: it was once an FDA-approved pharmaceutical. The branded product, Geref (later Geref Diagnostic), completed full FDA review and was approved for diagnosing growth hormone deficiency — a regulatory history that most other compounded peptides simply do not have. The manufacturer, EMD Serono, later discontinued it for commercial reasons, not because of safety or efficacy concerns.

That history shapes how sermorelin pricing works today. Because the branded product no longer exists on the US market, there is no extreme brand-versus-compounded price gap like you see with tesamorelin, where brand-name Egrifta WR can cost tens of thousands of dollars annually while compounded versions run in the hundreds. With sermorelin, the entire market operates through compounding pharmacies and gray-market research vendors. The price range is narrower, and the decisions are simpler — but the questions worth asking before spending are no less important.

This guide covers every price tier, what the Astra Health Sermorelin Price Index of 15 US telehealth providers shows about current costs, how the research vendor market compares, what insurance does and does not cover, and what the clinical evidence actually supports at these price points.

Sermorelin price comparison by source

Sermorelin's regulatory background: why it's different from most compounded peptides

Most compounded peptides available through telehealth — BPC-157, CJC-1295, ipamorelin, TB-500 — were never FDA-approved for any indication. They enter the market through research vendor channels and compounding pharmacies under frameworks that have no prior FDA review as a foundation.

Sermorelin is different. The FDA approved Geref in the 1990s for a specific diagnostic purpose: evaluating pituitary capacity to secrete growth hormone in patients with suspected deficiency. That process required clinical trials demonstrating the molecule was safe for human injection, manufacturing review, and ongoing post-market surveillance. When EMD Serono discontinued Geref in the early 2000s, the FDA's records documented the discontinuation as commercially motivated, not driven by safety or effectiveness concerns. That distinction matters, because FDA regulations treat drugs discontinued for commercial reasons differently from those pulled for safety problems when it comes to compounding access.

The practical result: sermorelin is not a controlled substance, is not on the FDA's restricted compounding list, and is not subject to the Category 2 restrictions that currently limit compounding of BPC-157 and TB-500. Licensed 503A compounding pharmacies can prepare sermorelin for individual patients pursuant to a valid prescription from a licensed physician. This is one of the clearest regulatory positions of any compounded peptide currently available through telehealth channels in the United States.¹

Telehealth pricing: $91–$259 per month across 15 providers

The Astra Health Sermorelin Telehealth Price Index, published July 2026 and covering 15 US providers, tracked effective monthly costs ranging from $91 to $259 — a relatively tight band compared to what you see with newer peptides where early-market pricing is still volatile. "Effective monthly cost" in the index accounts for prepayment requirements and membership fees, not just the headline advertised price. Effective cost is the metric that matters: the true out-of-pocket per month on the provider's actual lowest available plan.

At the low end, Astra Health itself published a rate of $91 per month on a six-month prepaid plan. AgelessRx listed at $99 per month with no membership fee. The middle of the market — where most providers cluster — runs $115 to $200 monthly. Providers at the higher end of the range, such as Maximus and Fridays, ran $259 per month for programs that include more extensive physician oversight and built-in monitoring.

Several factors drive price variation across providers:

• Consultation bundling: Some programs include provider consultations in the monthly fee; others charge separately for initial and follow-up visits, adding $75 to $200 per consultation.
• Lab work: Baseline and follow-up IGF-1 testing, which most responsible programs require, costs $100 to $300 when billed separately. Programs that include this in the monthly fee appear more expensive at the headline level but may actually cost less in total.
• Prepayment discounts: Most providers offer lower effective monthly rates on 3- or 6-month prepaid plans compared to month-to-month subscriptions. The difference commonly runs $30 to $70 per month.
• Supply configuration: Vial concentration, monthly peptide volume, and whether injection supplies (syringes, bacteriostatic water, alcohol swabs) are included or billed separately all affect the total cost.

When comparing providers, the only accurate comparison is all-in monthly cost: peptide, consultation, labs if required, supplies, and any platform or membership fees. Programs that advertise at $99 but require $150 in separate lab work are not cheaper than programs that advertise at $199 and include labs.

What the first month actually costs

First-month costs for a telehealth sermorelin program are typically higher than the ongoing monthly rate because they include the initial clinical evaluation. A realistic first-month budget breaks down as follows:

• Initial telehealth consultation: $75 to $200 for the clinical intake, medical history review, and prescription — often $0 if bundled into the program fee
• Baseline labs (IGF-1, metabolic panel): $100 to $300 when ordered separately through a third-party lab service; sometimes included in programs at the higher end of the price range
• Compounded sermorelin supply (first month): $91 to $259 depending on the provider and plan structure
• Injection supplies: Typically included; when billed separately, adds $15 to $30

Total first-month outlay: $250 to $500 is a realistic planning range for most programs. Subsequent months drop to the listed monthly rate once no new labs are needed and follow-up consultations are infrequent. Some programs schedule quarterly follow-up visits at $75 to $150 each; others offer unlimited provider messaging at no additional charge.

Getting an itemized cost breakdown before committing — not just the peptide price — is the only way to accurately compare across programs.

Gray-market research vials: $26–$79

Online research vendors sell sermorelin labeled "for research use only" at prices typically ranging from $26 to $79 per 5 mg or 10 mg vial, with no prescription required. Per-milligram, this represents a cost roughly 8 to 15 times lower than the supervised clinical route. The price difference is real. So is what the price difference represents.

The research vendor channel operates outside the 503A compounding framework. There is no prescribing physician, no required baseline labs, no follow-up monitoring, and no pharmacist or physician reviewing the buyer's medical history for contraindications. Product quality varies significantly. Reputable vendors in this market publish certificates of analysis from independent third-party laboratories — verifiable by the batch number — showing HPLC purity and mass spectrometry confirmation. Others provide in-house testing only, which is widely considered a lower standard in the research community.

Dr. Pieter Cohen, Associate Professor of Medicine at Harvard Medical School, described the fundamental problem with online peptide markets directly:

"When you're talking about peptides being promoted online, those health claims have not been vetted by any expert group, the FDA, or anyone else. The health claims are divorced from data." — Dr. Pieter Cohen, Harvard Medical School³

That concern applies to the research vendor channel across all peptides, including sermorelin. The absence of physician oversight means no one is monitoring for IGF-1 elevation, glucose tolerance changes, or other responses that a licensed program would track through follow-up lab work. The cost saving represents the removal of that monitoring infrastructure, not a more efficient delivery of the same clinical product.

Insurance: what's covered and what isn't

Sermorelin is not covered by insurance for the off-label purposes most patients seek it: anti-aging, body composition, general growth hormone optimization, sleep quality, or recovery. The landscape is straightforward:

• Off-label use (body composition, anti-aging, wellness): Not covered by commercial insurance, Medicare, or Medicaid. Denials are consistent across insurers for these indications.
• Compounded sermorelin: Not covered regardless of indication. Even if a physician could establish a clinical rationale, compounded preparations are excluded from standard insurance coverage.
• Geref for growth hormone deficiency diagnosis: The original approved indication. Coverage would theoretically exist through standard drug benefits — but there is no brand product on the market, and no insurance infrastructure supports this pathway in practice.
• HSA and FSA accounts: May be usable for compounded sermorelin when prescribed by a licensed physician for a qualifying medical condition. This depends on individual plan rules and documentation requirements. Confirm with your plan administrator before assuming eligibility.

What the clinical evidence does and doesn't support at these price points

Sermorelin's evidence grade varies sharply depending on the indication. For its original FDA-approved diagnostic use — evaluating pituitary GH secretion capacity — the evidence basis is strong: controlled studies demonstrated that sermorelin injection produces a measurable, dose-dependent GH response that distinguishes pituitary GH deficiency from hypothalamic causes. That is what earned FDA approval and what gave the molecule its prior regulatory standing.⁴

For the off-label therapeutic uses most telehealth patients seek — body composition changes, sleep improvement, anti-aging protocols — the evidence sits at a considerably lower grade. Small studies in GH-deficient and GH-insufficient adults have documented increases in IGF-1 levels and some changes in lean body mass with sermorelin administration. What has not been demonstrated in large-scale randomized controlled trials is that these pharmacokinetic changes translate into the clinical outcomes most patients want: measurable fat loss, sustained muscle gain, or functional anti-aging benefits that outperform lifestyle modification alone.

This is a common pattern across growth hormone secretagogues. Raising GH levels through a pharmacological stimulus is not the same as demonstrating clinical benefit from that elevation. The American Medical Association has noted this gap directly for injectable peptides, pointing out that the clinical evidence base for most therapeutic uses remains far behind the marketing claims.²

For a patient weighing $150 to $200 per month against what the evidence actually shows for off-label therapeutic use, that gap between pharmacokinetic data and clinical outcome data is worth factoring into the cost-benefit calculation. Sermorelin's prior FDA approval and safety record give it a stronger regulatory foundation than most other compounded peptides — but that regulatory history does not substitute for Phase 3 efficacy data in the therapeutic indications most buyers are targeting.

How sermorelin cost compares to alternatives

Patients considering sermorelin for growth hormone optimization typically compare it against several other options:

• Synthetic HGH (compounded or clinic-dispensed): $600 to $1,200 or more monthly — a different regulatory pathway, directly supplying exogenous GH rather than stimulating natural release; carries DEA scheduling considerations and a distinct safety monitoring profile
• CJC-1295/Ipamorelin combination: $200 to $500 monthly through supervised programs — a commonly used growth hormone secretagogue combination with similar legal standing to sermorelin but no prior FDA approval history
• Tesamorelin (compounded): $150 to $700 monthly — a related growth hormone-releasing hormone analog with actual FDA approval for a specific indication and a more complex regulatory situation for compounding; see our tesamorelin cost guide for details
• GLP-1 medications (compounded semaglutide or tirzepatide): $99 to $349 monthly at current telehealth pricing — a different mechanism targeting weight loss through appetite and metabolic pathways; typically produces larger total weight changes than GH secretagogues for most patients
• MK-677 (ibutamoren): $40 to $120 monthly through research vendors — an oral GH secretagogue with no legal compounding pathway and a more contested safety profile; not available through supervised clinical programs

Sermorelin occupies the lower end of the compounded GH secretagogue price range, which makes it the entry point that most telehealth platforms recommend for first-time GH optimization protocols. Its prior FDA approval and established compounding infrastructure give it a regulatory foundation no other compounded GH peptide currently matches. Whether that regulatory history is worth the monthly commitment compared to alternatives depends on the patient's specific clinical goals — a conversation that belongs with a licensed physician rather than on a pricing comparison page.

Questions to ask before committing to a sermorelin program

• What is the all-in monthly cost — consultation, peptide, labs, supplies, and follow-up? Low base prices that grow with separately billed components misrepresent the actual commitment. Get an itemized estimate before enrolling.
• Is baseline and follow-up IGF-1 monitoring included? A sermorelin protocol without any lab monitoring is not providing the full clinical oversight a physician-supervised program should include. Ask specifically whether IGF-1 testing is included or separately billed.
• Can the pharmacy provide a batch-specific certificate of analysis from an independent laboratory? Reputable 503A compounding pharmacies test production batches for sterility and purity. If a pharmacy cannot provide a COA from a genuinely independent lab, that is a quality flag.
• What is the pharmacy's 503A licensing status? 503A pharmacies are state-regulated. Any licensed clinical program dispensing sermorelin should be filling through a state board-licensed pharmacy. Confirm that the compounding pharmacy has current licensure in your state.
• Are prepayment discounts worth the commitment? Six-month prepaid plans offer better per-month rates but require a larger upfront payment. If you are not certain you will continue past the first few months, a month-to-month plan at a higher monthly rate may carry less financial risk.